The earnings call reflects significant progress in clinical trials and regulatory approvals, particularly for Annamycin. New patents and drug names bolster future market positioning. However, financial constraints and potential EU approval delays pose challenges.

Company Guidance -

Q3 2025

During the Moleculin Biotech First Quarter 2025 Update Conference Call, several key metrics and guidance were discussed. The company announced the initiation of the Phase 3 MIRACLE trial for Annamycin, with 38 sites selected globally and the first patient already treated. The European Medicines Agency provided approval for the trial across nine EU countries, marking a significant milestone. Moleculin also revealed additional patent protections for Annamycin, extending its composition of matter protection into at least 2040. They highlighted the progress of their MB-107 clinical trial for advanced soft tissue sarcoma and the investigator-sponsored trial of WP1066, which has recruited seven patients at Northwestern University. Financially, Moleculin ended the quarter with $8 million in cash and anticipates needing to raise approximately $15 million to fund operations into the first quarter of 2026. They aim to unblind data from the first 45 patients in the MIRACLE trial by the end of 2025, which they believe will be pivotal for potential new drug approval. Their market cap stands at over $14 million, with 14.1 million shares outstanding and a three-month average trading volume of nearly 6 million shares per day.

Phase 3 MIRACLE Trial Progress

The Phase 3 MIRACLE trial for Annamycin has officially started with the first patient treated, and 38 sites selected worldwide. The European Medicines Agency has approved the trial in all nine countries requested.

New Drug Name and Patent Protection

The World Health Organization has recognized a new generic drug name for Annamycin as naxtarubicin, and additional patents have been secured, extending protection into at least 2040.

MB-106 Phase 2 Trial Results

The MB-106 trial shows promising results with the first patient achieving a nearly two-year complete remission, and additional subjects maintaining complete remission.

WP1066 Progress

WP1066 is in an investigator-sponsored clinical trial showing activity in the treatment of brain tumors, with rapid patient recruitment at Northwestern University.

Financial Health and Market Activity

Market cap is over $14 million, with healthy trading volume, and plans to raise $15 million to support ongoing trials.

Moleculin Biotech (MBRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MBRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.27 / -	-2.85	―	―	―
Aug 13, 2025	2025 (Q2)	-0.43 / -0.49	-1.7	71.18% (+1.21)	―	―
May 14, 2025	2025 (Q1)	-0.56 / -0.69	-2.02	65.84% (+1.33)	―
Mar 24, 2025	2024 (Q4)	-1.28 / 0.25	-5.02	104.98% (+5.27)	―
Nov 11, 2024	2024 (Q3)	-2.44 / -2.85	-2.85	0.00% (0.00)	―
Aug 14, 2024	2024 (Q2)	-2.51 / -1.70	-3	43.33% (+1.30)	―	―
May 13, 2024	2024 (Q1)	-3.53 / -2.02	-4.2	51.90% (+2.18)	―
Mar 22, 2024	2023 (Q4)	-3.23 / -5.02	-3.45	-45.51% (-1.57)	―
Nov 13, 2023	2023 (Q3)	-3.35 / -2.85	-4.5	36.67% (+1.65)	―
Aug 11, 2023	2023 (Q2)	-4.10 / -3.00	-3.6	16.67% (+0.60)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MBRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$0.66	$0.67	+1.52%
May 14, 2025	$1.07	$0.99	-7.48%
Mar 24, 2025	$1.09	$1.06	-2.75%
Nov 11, 2024	$2.55	$2.51	-1.57%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Moleculin Biotech (MBRX) report earnings?

Moleculin Biotech (MBRX) is schdueled to report earning on Nov 17, 2025, TBA (Confirmed).

What is Moleculin Biotech (MBRX) earnings time?

Moleculin Biotech (MBRX) earnings time is at Nov 17, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MBRX EPS forecast?

MBRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.27.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing